Mutations in JAK1 and JAK2 significantly downregulate the PD-L1 gene expression in MSI-H/dMMR CRCs, melanoma, and endometrial tumors, leading to resistance to PD-1 therapy [55,56]. This evidence concerns the gene PDCD1 and melanoma.